Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
- Kyowa Kirin Kicks Off Global PIII for Adult X-Linked Hypophosphatemia
December 7, 2015
- Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
- Nichi-Iko Sells Off Shares Held in South Korean Firm
December 3, 2015
- GSK’s Drug Supplies Disrupted by Manufacturing Woes Overseas
December 2, 2015
- Japan NDA for IBS-C Drug Linaclotide Planned in 2016: Astellas
December 2, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
- Kyowa Kirin Launches Japan PIII Study for Regpara Successor
December 2, 2015
- Ole Moelskov Bech to Lead Novo Nordisk Japan from January
December 2, 2015
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
- Chris Hourigan Named as New President of Janssen Japan Unit
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
- Eisai to Venture into Chinese Generic Market by Acquiring Local Firm
November 30, 2015
- Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January
November 30, 2015
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…